Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of ...

Biogen Inc. (BIIB) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $4.36 per share a year ago. These ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...